These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 29262504

  • 21. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP.
    Clin Cancer Res; 2006 Mar 01; 12(5):1487-93. PubMed ID: 16533772
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
    Lokman NA, Pyragius CE, Ruszkiewicz A, Oehler MK, Ricciardelli C.
    Transl Res; 2016 May 01; 171():83-95.e1-2. PubMed ID: 26925708
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.
    Gynecol Oncol; 2006 Dec 01; 103(3):831-40. PubMed ID: 16919315
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer.
    Daponte A, Kostopoulou E, Papandreou CN, Daliani DD, Minas M, Koukoulis G, Messinis IE.
    Anticancer Res; 2008 Dec 01; 28(3B):1905-10. PubMed ID: 18630479
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
    Zhang J, Li ZY, Duan XJ, Fan XM, Liu WN, Li YH.
    Zhonghua Zhong Liu Za Zhi; 2016 Dec 23; 38(12):904-908. PubMed ID: 27998466
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
    Chai Y, Wu W, Zhou C, Zhou J.
    Arch Gynecol Obstet; 2012 Aug 23; 286(2):465-71. PubMed ID: 22476353
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
    Mandelin E, Lassus H, Seppälä M, Leminen A, Gustafsson JA, Cheng G, Bützow R, Koistinen R.
    Cancer Res; 2003 Oct 01; 63(19):6258-64. PubMed ID: 14559812
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay MHE, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.
    Int J Gynecol Cancer; 2017 May 01; 27(4):708-713. PubMed ID: 28441251
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.